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Th17, a culprit in psoriasis
Etanercept, a fusion between tumor necrosis factor (TNF) 
receptor and immunoglobulin, has been used to block TNF 
for the treatment of psoriasis, an autoimmune disease that 
affects 1–2% of the population in North America and Europe. 
Zaba and colleagues recently demonstrated that psoriasis 
disease improvement following etanercept treatment cor-
related with decreases in dendritic cell and Th17 cell prod-
ucts and effector molecules in the early weeks, whereas final 
disease resolution was associated with late downregulation 
of Th1 cells after several months. Specifically, etanercept 
acts early to inhibit inflammatory dendritic cell maturation 
and cytokine production. Ultimately, this modulation leads 
to decreased Th17 cell function. Although Th17 cells may 
drive keratinocyte hyperplasia and inflammatory cytokine 
production, Th1 cells still appear to be critical for leukocyte 
activation and sustaining interferon-γ signaling pathways. 
Additional research is necessary to tease out the precise roles 
of Th1 and Th17 cells in psoriasis. (J Exp Med 204:3183–94, 
2007)
The cycles of hair regeneration
Cyclic activation of hair stem cells in the follicle bulge facili-
tates regeneration throughout adult life. Recently, Plikus and 
colleagues described periodic expression of bone morpho-
genetic protein 2 (Bmp2) and Bmp4 with low expression 
during early propagating anagen and high expression during 
late autonomous anagen. The dermal macroenvironment was 
implicated as the source of periodic Bmp2 and Bmp4 expres-
sion. Reduction of BMP signaling in transgenic mice reduced 
the period of refractory telogen, and delivery of BMP protein 
converted competent telogen tissue to refractory in normal 
mice. Interestingly, transplantation of skin from mice over-
expressing a BMP antagonist onto a wild-type host animal 
implicated both donor and host follicles in cycling and indi-
cated that the deciding force was overall BMP equilibrium. 
These results suggest that BMPs may be the elusive “chalone” 
inhibitors of anagen development that researchers hypothe-
sized more than 50 years ago. (Nature 451:340–4, 2008)
Melanoma initiator uncovered
Cells responsible for tumor initiation and tumor growth have 
been described in human hematological malignancies as 
well as in solid tumors. Schatton and colleagues recently 
identified a subpopulation of cells enriched for initiation of 
malignant melanoma, and these cells expressed the chemo-
resistance mediator ABCB5. Human-to-NOD/SCID mouse 
xenotransplantation studies revealed that ABCB5+ popula-
tions resulted in tumor initiation and development. In addi-
tion, genetic lineage tracking experiments demonstrated that 
ABCB5+ cells yielded both ABCB5+ and ABCB5– cells, where-
as ABCB5– cells gave rise only to ABCB5– cells. These results 
tout the self-renewal and differentiation abilities of ABCB5+ 
cells. Importantly, administration of a monoclonal antibody 
directed against ABCB5 inhibited tumor growth as well as 
tumor formation in the nude mouse melanoma xenograft 
model. Thus, targeting these malignant melanoma-initiating 
cells may prove to be an important and novel therapeutic 
strategy that may overcome the common chemoresistance in 
this type of cancer. (Nature 451:345–9, 2008)
Relay of pain
Innervation of the stratum granulosum of the epidermis 
occurs via unmyelinated neurons that express the mas-
related G-protein-coupled receptor (Mrgprd). Using patch 
clamp experiments to characterize neurons from mice that 
express green fluorescent protein concurrently with Mrgprd, 
Dussor and colleagues revealed that these neurons displayed 
nociceptor-like characteristics, including small-diameter 
cell bodies, long-duration action potentials, action poten-
tials with overshoots, Na+ currents that are resistant to tetro-
dotoxin, and Ca2+ currents that are inhibited by opioids. 
Moreover, these neurons exhibit currents selectively evoked 
by extracellular ATP. These Mrgprd+ neurons likely respond 
to the release of ATP, and possibly other molecules, by 
epidermal keratinocytes. Keratinocytes may serve as the 
intermediaries that receive the pain sensations and initiate 
signaling to the central nervous system via these specific 
neurons. (J Neurophysiol, published online 30 January 2008; 
doi:10.1152/jn.01396.2007)
The oncogene paradox
The activated mutant BRAF oncogene BRAFV600E induces 
uncontrolled proliferation in melanomas, yet causes senes-
cence in benign nevi. Clues into these seemingly contradic-
tory roles of BRAF were recently uncovered when Wajapeyee 
and colleagues performed a genome-wide RNA interfer-
ence screen of 28,000 genes to identify factors required for 
the mutant to block cellular proliferation. Seventeen factors, 
including the secreted protein insulin growth factor binding 
protein 7 (IGFBP7), were found to bypass the BRAFV600E-
mediated proliferation. IGFBP7 induced senescence and 
apoptosis via autocrine and/or paracrine feedback. This 
mechanism is dependent on inhibition of BRAF–MEK–ERK 
signaling. Loss of IGFBP7 expression is a critical step in 
the development of a BRAFV600E melanoma, and this loss 
occurs primarily by epigenetic silencing through hypermeth-
ylation of the promoter. Additionally, treatment of these mel-
anomas with recombinant IGFBP7 suppressed tumor growth. 
Thus, IGFBP7 may prove to be a useful target for treating 
malignancies harboring activating BRAF mutations. (Cell 
132:363–74, 2008)
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